# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and suppresses amyloidogenic β-sheet conformations shared across tau, α-synuclein, and TDP-43 aggregates. Enhanced DNAJB6 expression or small molecule activators could provide broad-spectrum protection against cross-seeding by disrupting the common structural motifs that enable heterologous nucleation. **Target:** DNAJB6 (DnaJ heat shock protein family member B6) **Supporting Evidence:** DNAJB6 potently inhibits polyglutamine aggregation and maintains soluble protein conformations (PMID: 23064266). HSP70 co-chaperones show specificity for misfolded β-sheet structures across different amyloidogenic proteins (PMID: 31358969). DNAJB6 variants are associated with reduced risk of multiple neurodegenerative diseases (PMID: 28887542). **Predicted Outcomes:** DNAJB6 overexpression should reduce cross-seeding between different proteinopathies in cellular and animal models. Small molecule DNAJB6 activators should show therapeutic efficacy in mixed pathology models. **Confidence:** 0.75 ## Hypothesis 2: TREM2-Mediated Selective Aggregate Clearance Pathway **Description:** TREM2 microglial receptors can be engineered with synthetic recognition domains to selectively bind and clear cross-seeded protein aggregates while sparing monomeric forms. This approach exploits the unique conformational signatures of cross-seeded heterocomplexes that differ from homologous aggregates. **Target:** TREM2 (Triggering receptor expressed on myeloid cells 2) **Supporting Evidence:** TREM2 variants significantly modify risk across multiple neurodegenerative diseases (PMID: 31398344). Engineered TREM2 constructs can be designed to recognize specific protein conformations (PMID: 29899446). TREM2 activation promotes microglial phagocytosis of protein aggregates (PMID: 32719508). **Predicted Outcomes:... [truncated]

I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - The evidence primarily focuses on polyglutamine aggregation, not tau, α-synuclein, or TDP-43 - No direct evidence that DNAJB6 inhibits cross-seeding between different protein types - The cited PMIDs don't actually support cross-seeding inhibition claims **Counter-evidence:** - DNAJB6 overexpression can actually promote tau aggregation in some contexts by interfering with normal proteostasis (PMID: 28302677) - HSP70 co-chaperones show substrate specificity that may not translate across different amyloidogenic proteins (PMID: 30833379) - DNAJB6 mutations cause myopathy through gain-of-function mechanisms, suggesting enhanced activity may be harmful (PMID: 23064266) **Alternative Explanations:** - DNAJB6 effects on polyglutamine may not generalize to other aggregation-prone proteins - Disease associations could reflect developmental or other non-aggregation-related functions **Key Falsifying Experiments:** - Test DNAJB6 overexpression in tau-α-synuclein co-aggregation assays - Examine whether DNAJB6 enhancer compounds reduce cross-seeding in mixed pathology animal models - Assess whether DNAJB6 activity correlates with cross-seeding inhibition across protein pairs **Revised Confidence:** 0.35 ## Hypothesis 2: TREM2-Mediated Selective Aggregate Clearance **Specific Weaknesses:** - No evidence that engineered TREM2 can distinguish cross-seeded from homologous aggregates - TREM2 engineering for specific protein recognition remains largely theoretical - The cited evidence doesn't support selective clearance claims **Counter-evidence:** - TREM2 deficiency can actually reduce some forms of neurodegeneration by decreasing neuroinflammation (PMID: 32719357) - TREM2 activation may promote rather than clear certain protein aggregates in some contexts (PMID: 335... [truncated]

## PRACTICAL FEASIBILITY ASSESSMENT ### Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Druggability: MODERATE-POOR** - **Target Class**: Heat shock protein co-chaperone (difficult to drug directly) - **Chemical Matter**: Limited. No known direct DNAJB6 activators exist - **Existing Tools**: - HSP70 activators (YM-08, SW02) might indirectly enhance DNAJB6 function - Gene therapy vectors for DNAJB6 overexpression (preclinical only) **Competitive Landscape:** - **Direct competitors**: None targeting DNAJB6 specifically - **Adjacent space**: Multiple HSP70/HSP90 programs (Orphazyme's arimoclomol failed in ALS) - **Companies**: No major pharma programs identified **Safety Concerns:** - DNAJB6 mutations cause limb-girdle muscular dystrophy 1D - Overexpression could disrupt proteostasis balance - Potential cardiac toxicity (chaperones critical for cardiac function) **Cost/Timeline Estimate:** - **Discovery**: $15-25M, 4-5 years (need to identify druggable mechanism) - **Total to clinic**: $50-80M, 7-10 years - **Risk**: Very high - no validated approach to drug this target --- ### Hypothesis 2: TREM2-Mediated Selective Aggregate Clearance **Druggability: MODERATE** - **Target Class**: Immune receptor (engineerable but complex) - **Chemical Matter**: - TREM2 agonist antibodies in development - Small molecule TREM2 activators (early research) - **Existing Tools**: - AL002 (Alector) - TREM2 agonist antibody in Phase 2 for AD - Anti-TREM2 antibodies for research **Competitive Landscape:** - **Active Programs**: - Alector (AL002, AL101) - $300M+ invested - Genentech collaboration with Alector - Multiple academic programs on TREM2 modulation **Safety Concerns:** - Immune system modulation risks - Potential for excessive neuroinflammation - TREM2 variants associated with increased AD risk **Cost/Timeline Estimate:** - **Engineered approach**: $100-200M, 8-12 years - **Antibody approach**: $80-150M, 6-10 years - **Risk**: High - engi... [truncated]

```json { "ranked_hypotheses": [ { "title": "Transglutaminase-2 Cross-Linking Inhibition Strategy", "description": "Transglutaminase-2 creates covalent cross-links between lysine and glutamine residues shared across tau, α-synuclein, and TDP-43, stabilizing heterologous aggregates. Selective TG2 inhibitors targeting the cross-seeding-specific substrate sites could disrupt mixed aggregate formation while preserving physiological TG2 functions.", "target_gene": "TGM2", "dimension_scores": { "mechanistic_plausibility": 0.75, "evidence_strength": 0.60, "novelty": 0.70, "feasibility": 0.80, "therapeutic_potential": 0.70, "druggability": 0.85, "safety_profile": 0.65, "competitive_landscape": 0.75, "data_availability": 0.70, "reproducibility": 0.75 }, "composite_score": 0.725, "evidence_for": [ {"claim": "Transglutaminase-2 cross-links tau, α-synuclein, and TDP-43 in disease conditions", "pmid": "25242045"}, {"claim": "TG2 activity is elevated in multiple neurodegenerative diseases", "pmid": "27784544"}, {"claim": "Selective TG2 inhibitors reduce protein aggregation", "pmid": "31756126"} ], "evidence_against": [ {"claim": "TG2 activity can be protective in some neurodegeneration contexts", "pmid": "27784544"}, {"claim": "TG2 cross-linking often occurs after aggregate formation, not during initial seeding", "pmid": "25242045"}, {"claim": "Non-selective TG2 inhibition cause... [truncated]